ARDX
ARDELYX, INC.
Overview
Ardelyx designs and commercializes medicines based on tenapanor, a sodium/hydrogen exchanger inhibitor. The company markets IBSRELA for irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in dialysis patients, and is developing additional NHE3 inhibitors for multiple therapeutic areas.
ARDELYX, INC is a Healthcare company operating in Biotechnology with a $1.57B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 2, 2026).
18 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-04-3022 Q&A exchanges
- Q4 FY2025Earnings2026-02-2015 Q&A exchanges
- Q3 FY2025Earnings2025-10-3014 Q&A exchanges
- Q2 FY2025Earnings2025-08-0417 Q&A exchanges
- Q1 FY2025Earnings2025-05-0122 Q&A exchanges
- Q4 FY2024Earnings2025-02-2025 Q&A exchanges
- Q3 FY2024Earnings2024-10-3120 Q&A exchanges
- Q2 FY2024Earnings2024-08-0113 Q&A exchanges
- Q1 FY2024Earnings2024-05-0214 Q&A exchanges
- Q4 FY2023Earnings2024-02-2224 Q&A exchanges
- Q3 FY2023Earnings2023-10-3113 Q&A exchanges
- Q2 FY2023Earnings2023-08-0219 Q&A exchanges
- Q1 FY2023Earnings2023-05-0311 Q&A exchanges
- Q4 FY2022Earnings2023-03-0217 Q&A exchanges
- Q3 FY2022Earnings2022-11-0618 Q&A exchanges
- Q2 FY2022Earnings2022-08-078 Q&A exchanges
- Q1 FY2022Earnings2022-05-0517 Q&A exchanges
- Q4 FY2021Earnings2022-02-2816 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-02EPS— vs $-0.04—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-02 | — | $-0.04 | — | — | — | — | EODHD |
Source: EODHD. ARDX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ARDX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.09 | $0.73 | +48.7% | -6.3% | -4.0% |
| Q4 FY2026 | $1.10 | $0.79 | +39.0% | -7.1% | -9.4% |
| Q3 FY2026 | $1.19 | $0.85 | +40.2% | -0.5% | +1.9% |
| Q2 FY2026 | $1.53 | $1.05 | +45.9% | -3.7% | -4.3% |
| Q1 FY2025 | $1.42 | $1.00 | +42.0% | +0.5% | +0.4% |
| Q4 FY2025 | $1.35 | $0.99 | +35.9% | -1.4% | +0.2% |
| Q3 FY2025 | $1.22 | $0.84 | +45.7% | +0.4% | +1.6% |
| Q2 FY2025 | $1.35 | $0.93 | +45.5% | -6.3% | -4.8% |
| Q1 FY2024 | $1.53 | $1.04 | +46.8% | -4.3% | -5.2% |
| Q4 FY2024 | $1.70 | $1.14 | +49.0% | -9.1% | -9.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Michael RaabCEO10 mo17 callsCurrentSample
CEO since 2025 • 1/4 beats (25%) • last guidance raise Q2 FY2026
- Susan HohenleitnerCFO7 mono recorded callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Justin A RenzCFO10 mo16 callsCurrentSample
CFO since 2025 • 1/4 beats (25%) • last guidance cut Q1 FY2026
- Felecia EttenbergChief Legal Officer2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance raise Q1 FY2026
- Rajani DinavahiChief Medical Officer2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last guidance cut Q3 FY2026
- Laura A WilliamsChief Patient Officer10 mo2 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ARDX.
$ curl https://api.spokenalpha.com/v1/companies/ARDXFAQ
Frequently asked about ARDX
Where can I find ARDELYX, INC.'s (ARDX) earnings call transcripts?
Spoken Alpha indexes ARDX's earnings call transcripts at https://spokenalpha.com/companies/ARDX. Each call links to attributed speakers and parsed analyst Q&A. ARDELYX, INC.'s own investor relations page is at https://ir.ardelyx.com/.
When was ARDELYX, INC.'s most recent earnings call?
ARDELYX, INC. (ARDX) held its most recent earnings call on 2026-04-30, covering fiscal Q1 2026.
What sector is ARDX in?
ARDELYX, INC. (ARDX) operates in the Healthcare sector (Biotechnology industry).